Oxular

Recent Finacing

Equity

Recent Raise

$37.7M

Oxular develops biodegradable sustained‑release ocular formulations and an illuminated microcatheter for suprachoroidal delivery, designed to provide up to 12‑month treatment for retinal diseases from a single administration.